Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Naptumomab estafenatox (Primary) ; Obinutuzumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; HER2 negative breast cancer; Liver cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NeoTX Therapeutics

Most Recent Events

  • 18 Mar 2025 Planned End Date changed from 1 Oct 2026 to 1 Mar 2027.
  • 18 Mar 2025 Planned primary completion date changed from 1 Oct 2026 to 1 Mar 2027.
  • 21 Feb 2024 Planned End Date changed from 30 Aug 2025 to 1 Oct 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top